Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Veracyte Inc Logo

ARKW Holdings of Veracyte (VCYT) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
January 7, 2022BUY14.800k0.0148%ARKW
January 4, 2022BUY43.772k0.0432%ARKW
December 14, 2021BUY50.910k0.0499%ARKW
November 30, 2021BUY12.182k0.01%ARKW
November 29, 2021BUY45.574k0.0395%ARKW

Key Statistics

DateMay 03, 2022Revenue
Expected0
Actual$67.78m
EPS
Expected-$0.24
Actual-$0.20
🕵🏼Found In🏷Last Price
ARKKARKWARKG$18.37
⚖️Weighting🧢Market Cap
1.16%$1.31b
🏋🏿‍♂️Weight Rank In ARKW🧮Price to Sales
245.24
🏋️‍♀️Weight Rank Across All Funds🌏Country
27🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$14.851.38%
Description
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Website
www.veracyte.com